Noile-Immune Biotech Inc.
4893ノイルイミューン・バイオテック株式会社
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-13For the first half of the fiscal year to 2026-12: Ordinary income ¥-0.4 billion, Net income ¥-0.4 billion.
| This period | Year on year | |
|---|---|---|
| Ordinary profit | −¥371m | — |
| Net profit to owners | −¥372m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4893/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2025-12-31- Revenue
- ¥5m
- Net income
- −¥794m
- ROE
- —
- Equity ratio
- 97.8%
- Dividend / share
- —
- Employees
- 23
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥5m | −¥794m | ¥4,012m | ¥3,932m | — | ¥-18.33 | −¥752m |
| 2024-12-31 | ¥8m | −¥964m | ¥4,800m | ¥4,725m | — | ¥-22.28 | −¥888m |
| 2023-12-31 | ¥317m | −¥1,130m | ¥5,779m | ¥5,687m | — | ¥-27.25 | −¥873m |
| 2022-12-31 | ¥626m | −¥387m | ¥4,641m | ¥4,301m | — | ¥-9.87 | −¥107m |
| 2021-12-31 | ¥101m | −¥795m | ¥4,271m | ¥4,185m | — | ¥-20.75 | −¥777m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -158.2232 | 0.1 |
| Equity ratio, % | 97.8 | 100 |
| Revenue growth | -0.341 | 1 |
| Net income growth | 0.1772 | 54 |
| Operating cash flow / assets | -0.1875 | 2.7 |
Via /v1/companies/4893/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4893/votingOwnership changes
All companies →- 2026-10-22
OKASAN SECURITIES CO., LTD. reduced holdings in Noile-Immune Biotech Inc. (4893) to 17.51% from 18.26%.
- 2026-10-16
OKASAN SECURITIES CO., LTD. reduced holdings in Noile-Immune Biotech Inc. (4893) to 18.26% from 19.29%.
- 2026-10-09
OKASAN SECURITIES CO., LTD. disclosed a 19.29% stake in Noile-Immune Biotech Inc. (4893), crossing the 5% reporting threshold.
- 2026-10-09
Holdings of OKASAN SECURITIES CO., LTD. in Noile-Immune Biotech Inc. (4893) moved above 10% (new -> 19.29%).
- 2024-07-31
TSURUKAME CO.,LTD reduced holdings in Noile-Immune Biotech Inc. (4893) to 20.63% from 21.90%.
- 2024-07-26
TSURUKAME CO.,LTD reduced holdings in Noile-Immune Biotech Inc. (4893) to 21.90% from 25.14%.
- 2024-06-21
TSURUKAME CO.,LTD reduced holdings in Noile-Immune Biotech Inc. (4893) to 25.14% from 26.82%.
- 2024-05-24
individual filer cut holdings in Noile-Immune Biotech Inc. (4893) to 4.55% from 5.57%, below the 5% threshold.
- 2024-03-06
TSURUKAME CO.,LTD reduced holdings in Noile-Immune Biotech Inc. (4893) to 26.82% from 27.90%.
- 2024-02-15
TSURUKAME CO.,LTD reduced holdings in Noile-Immune Biotech Inc. (4893) to 27.90% from 27.95%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| 岡三証券株式会社 | 2026-10-05 – 2026-10-16 | +9,050,000 | +16.96pt | — | — |
| 株式会社鶴亀 | 2024-02-14 – 2024-07-24 | -2,420,300 | −5.59pt | ¥259.82 | ¥168–301 |
| 株式会社アプリコット | 2024-06-10 – 2024-06-10 | -400,000 | −0.92pt | ¥244 | ¥244–244 |
| individual filer | 2024-05-16 – 2024-05-17 | -40,000 | −0.10pt | — | — |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4893/trades.
5% filings
Large shareholding reports on 4893| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-10-22 | OKASAN SECURITIES CO., LTD. | 17.51% | −0.75pt | — |
| 2026-10-16 | OKASAN SECURITIES CO., LTD. | 18.26% | −1.03pt | — |
| 2026-10-09 | OKASAN SECURITIES CO., LTD. | 19.29% | — | — |
| 2024-07-31 | TSURUKAME CO.,LTD | 20.63% | −1.27pt | pure investment |
| 2024-07-26 | TSURUKAME CO.,LTD | 21.90% | −3.24pt | pure investment |
| 2024-06-21 | TSURUKAME CO.,LTD | 25.14% | −1.68pt | pure investment |
| 2024-05-24 | individual filer | 4.55% | −1.02pt | — |
| 2024-03-06 | TSURUKAME CO.,LTD | 26.82% | −1.08pt | pure investment |
| 2024-02-15 | TSURUKAME CO.,LTD | 27.90% | −0.05pt | pure investment |
| 2023-07-05 | TSURUKAME CO.,LTD | 27.95% | — | pure investment |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- — issues
- Book value
- —
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 2
Held by: Takeda Pharmaceutical Company Limited 4502, SHIBUYA CORPORATION 6340
Purposes, all holdings and mutual flags via /v1/companies/4893/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| 武田薬品工業株式会社 | 8,119,800 | 18.75% |
| 株式会社鶴亀 | 7,159,550 | 16.53% |
| individual holder | 3,750,000 | 8.66% |
| KOREA SECURITIES DEPOSITORY-SAMSUNG | 3,678,720 | 8.49% |
| individual holder | 1,700,000 | 3.92% |
| 大和日台バイオベンチャー投資事業有限責任組合 | 1,349,200 | 3.11% |
| individual holder | 1,000,000 | 2.30% |
| individual holder | 1,000,000 | 2.30% |
| individual holder | 956,900 | 2.20% |
| individual holder | 760,000 | 1.75% |
Get this as JSON
GET /v1/companies/4893
GET /v1/companies/4893/financials
GET /v1/companies/4893/details
GET /v1/companies/4893/segments
GET /v1/companies/4893/voting
GET /v1/companies/4893/tender-offers
GET /v1/companies/4893/indicators
GET /v1/companies/4893/earnings-releases
GET /v1/events?ticker=4893
GET /v1/companies/4893/trades
GET /v1/companies/4893/cross-holdings
GET /v1/companies/4893/brief